2022 World Conference on Lung Cancer (ePosters)-EP08.01-016. A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy

EP08.01-016. A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy

Back to course

Pdf Summary

This review examined seven real-world studies on the treatment outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) after platinum-based chemotherapy. The studies took place in various countries, including India, China, the United States, Colombia, and Germany. The sample sizes ranged from 11 to 383 patients, and different treatment regimens were evaluated.<br /><br />The objective of the review was to assess the effectiveness of treatments for stage IV NSCLC patients who had progressed on or after platinum-based therapy. Only studies reporting real-world outcomes such as response rates, overall survival, and progression-free survival were included, while clinical trials were excluded. The study characteristics and results were extracted from the included studies.<br /><br />The review found that the real-world treatment outcomes for mNSCLC patients who had progressed on or after platinum-based therapy were poor. The median overall survival ranged from 3.4 months (nivolumab) to 18.0 months (irinotecan bevacizumab), while the median progression-free survival ranged from 2.8 months (apatinib) to 8 months (nivolumab). The overall response rates varied from 10% to 36% across the studies, with complete response being rare.<br /><br />The prevalence of brain metastases in the patient population ranged from 16.7% to 36.4%. Discontinuation due to adverse events ranged from 0% to 20% in the real-world studies.<br /><br />In conclusion, effective therapies that can delay progression and improve survival outcomes are urgently needed for patients with mNSCLC who have failed platinum-based chemotherapy.

Asset Subtitle

Cloe Ying Chee Koh

Meta Tag

Speaker Cloe Ying Chee Koh

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

metastatic non-small cell lung cancer

platinum-based chemotherapy

treatment outcomes

real-world studies

response rates

overall survival

progression-free survival

clinical trials

brain metastases

adverse events